Testing how fat tissue responds to somatostatin and epinephrine in obesity
Tests how fat cells respond to two drugs in adults with obesity.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 24 people, planned
- Started
- 1 Jan 2024
- Expected to end
- 1 Jan 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Somatostatin
- Epinephrine
- Record updated
- 22 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with overweight or obesity, especially with extra fat around the belly. It studies how fat tissue reacts to certain substances.
- Age
- 18 to 65 years
- Sex
- Men and women can join.
- Disease stage
- Overweight or obesity with a BMI of 29.0 - 40.0 kg/m2. Many have upper body or belly fat, with a waist-hip ratio above 0.85 in women or above 0.95 in men, or a lot of belly fat on a CT scan.
- Earlier treatment
- People cannot take medicines that change fat or fatty acid metabolism. People who took part in a study with an investigational drug must wait 12 weeks after it ends.
- Biomarker or test result
- Fasting glucose under 126 mg/dl (7 mmol/L) for people without diabetes. Hb at least 11.0 for women and at least 12 for men. Platelets above 100 000.
Main reasons for not taking part
- Heart or artery disease, or a past mini-stroke
- Persistent blood pressure above 160/95 despite medicine
- Liver cirrhosis or significant kidney problems
- Smokers
- Diabetes, or allergy to lidocaine or indocyanine green
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Males and females between 18 and 65 years of age who are able to comprehend instructions, follow study procedures, willing to sign an informed consent form, and consume an isoenergetic diet eating all meals from Mayo Clinical Research and Trials Unit for at least 3 days prior to study
- Overweight/Obese volunteers will have a BMI 29.0 - 40.0 kg/m2; o Upper body/visceral obesity (UBO) in women will be defined as those with a waist-hip ratio (WHR) > 0.85 and/or increased visceral fat by single slice CT scan, usually with > 120 cm2 of visceral fat by CT scanning or a visceral fat/total fat ratio of > 0.30, and/or biochemical evidence of metabolic syndrome as defined by adenosine triphosphate (ATP) III criteria (fasting plasma triglycerides ≥ 150 mg/dL, HDL-cholesterol < 50 mg/dL for women and < 40 mg/dL for men, fasting plasma glucose ≥ 100 mg/dL). Upper body obesity in men will be defined as a waist-hip ratio of >0.95 and/or increased visceral fat (visceral fat area > 120 cm2 or a visceral/total fat abdominal ratio by CT of > 0.40) by single slice CT scan and/or biochemical evidence of metabolic syndrome as defined by ATP III criterial. These visceral fat values are based upon the data collected at Mayo Clinic using our methods, and are correlated with dyslipidemia and hyperinsulinemia
- Female subjects are eligible if they meet the following criteria:; Are not pregnant or nursing; All women of childbearing potential will have a negative urine pregnancy test at screening and a negative urine pregnancy test within 48 hours before administering study drug
- Recent or current research participation in a study that involves an investigational drug. Participants in other clinical trials that involve an investigational drug will not be able to participate in this study until 12 weeks after their participation in the other study is complete or > than five half-lives of the compound, whichever is longer. If Yes look at consent form and f/u visits:
- Current use of medications that alter fatty acid or adipose metabolism possibly given: if yes, exclude
- Amount of blood drawn during the study (if our study plus this one draw ≥ 450 ml these should be separated by 8 weeks
- Previous labs:
- Fasting glucose < 126 mg/dl for non-diabetic UBO
- Hb ≥ 11.0 for women and ≥ 12 for men
- platelets > 100 000
Who cannot take part
- Concomitant use of medications that can alter free fatty acid metabolism or pose a drug-drug interaction: statins (if yes hold for 4 weeks and receive primary care provider's approval); Niacin; Fibrates; thiazolidinedione; Beta-blockers; Oral or injected corticosteroids or anabolic steroids; Linezolid; Dihydroergotamine; Phenelzine; daily phosphodiesterase inhibitors
- Individuals with a history of a disease process such as:; Ischemic heart disease; Atherosclerotic valvular disease; Persistent blood pressure greater than 160/95 despite antihypertensive medication; Peripheral artery disease; Any history of trans-ischemic attacks; Coronary artery disease; Liver cirrhosis; Significant renal impairment as documented in medical chart
- Diagnosis of Diabetes Mellitus
- Allergy to lidocaine
- Allergy to indocyanine green
- Smokers
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Mayo Clinic in RochesterRochester, United StatesContact: Madeline ReidTaking people
About the trial
What the trial wants to find out
Adults who gain most of their excess weight in the abdominal area typically do not respond to factors that "turn on" fat cells the same way as people who don't have excessive weight. Researchers are trying to understand why fat tissue responds differently in people with different body types.
The 2 groups in the trial
- Obesity GroupTreatment being tested
Subjects that have upper body obesity will receive somatostatin plus epinephrine
Treatment: Somatostatin and Epinephrine
- Lean GroupTreatment being tested
Subject wo are normal weight will receive somatostatin plus epinephrine
Treatment: Somatostatin and Epinephrine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Stimulation of Regional Lipolysis and Adipocyte Lipolysis Proteins
- Plain-language title
- Testing how fat tissue responds to somatostatin and epinephrine in obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06416969, who can take part
- Record updated
- 22 May 2026